Globe Life (GL) Could Be 2% Undervalued Following Higher 2026 Earnings Guidance

Globe Life (GL) is back on investor screens after a mixed second quarter that paired a miss on net operating income expectations with year over year improvement and a higher full year 2026 earnings outlook.

See our latest analysis for Globe Life.

The recent guidance upgrade and confirmed quarterly dividend appear to have supported sentiment around Globe Life, with the share price at $186.02 and a 90 day share price return of 23.13%. Over longer horizons, total shareholder returns of 33.47% over one year and 100.67% over five years indicate that momentum has been building rather than fading.

If you are reassessing your portfolio after Globe Life's latest update, this can be a useful moment to broaden your search and uncover 20 top founder-led companies

Globe Life’s sharp share price move now sits against improving underwriting results and a higher earnings outlook, as well as a quarter that still missed expectations. Are investors re-rating the business, or simply paying up on sentiment?

Most Popular Narrative: 2.1% Undervalued

Globe Life's most followed narrative points to a fair value of $190.09 per share, which sits slightly above the last close at $186.02.

The planned establishment of a Bermuda reinsurance affiliate is expected to significantly increase parent company free cash flow and financial flexibility by 2027 and beyond, providing greater capacity for share repurchases and/or strategic investments, positively impacting earnings per share.

Read the complete narrative. Read the complete narrative.

Investors may want to understand what sits behind that reinsurance move and buyback capacity story. The narrative focuses on measured revenue growth, firm margins and a higher future earnings multiple. It may be useful to explore which specific long term assumptions push the fair value above today’s price and how a 7.1% discount rate is used to support that outcome.

Result: Fair Value of $190.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Globe Life still faces execution and regulatory risks, including the Bermuda reinsurance plan and ongoing DOJ and SEC investigations, which could unsettle the current narrative.

Find out about the key risks to this Globe Life narrative.

Another View on Globe Life’s Valuation

The earlier narrative presents a fair value of $190.09 per share for Globe Life, supported by earnings projections and a required P/E of about 12x. On a simple P/E basis today, the picture is flatter. Globe Life trades at 11.8x earnings, which is in line with the US Insurance industry average of 11.8x.

Against a peer average P/E of 20x, that same 11.8x appears much lower. Yet the fair ratio sits close by at 11.5x, which suggests the gap to peers may reflect different growth and risk profiles rather than a clear pricing mistake. For investors, the question is whether current earnings quality and future growth are sufficient for the market to move closer to that higher peer multiple.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Globe Life looking mixed, you may want to take a closer look at the underlying data and the recent developments, and form your own view using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Globe Life?

If Globe Life has prompted a fresh look at your portfolio, you can use this momentum to widen your opportunity set with other focused stock ideas.

• Target potential mispricings by scanning for companies that combine quality and value using the 51 high quality undervalued stocks.
• Strengthen your income stream by checking out companies that offer reliable yield through the 9 dividend fortresses.
• Reduce portfolio stress by seeking companies with durable finances through the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com